For the year ending 2025-12-31, RKDA had -$3,983K decrease in cash & cash equivalents over the period. -$4,739K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -2,339 |
| Change in fair value of common stock warrant and option liabilities | 2,384 |
| Change in fair value of contingent consideration | -2,000 |
| Depreciation | 32 |
| Lease amortization | 122 |
| Amortization of note receivable discount | -69 |
| Gain on disposal of property and equipment | 0 |
| Gain on sale of intangible assets | 750 |
| Gain on receipt of above food ingredients, inc. common stock | 1,067 |
| Unrealized gain subsequent to receipt of above food ingredients, inc. common stock | 1,237 |
| Stock-based compensation | 234 |
| Credit loss | 4,745 |
| Write-down of inventories | 0 |
| Impairment of property and equipment | 0 |
| Write-down of non-controlling interest | 0 |
| Accounts receivable and other receivables | -165 |
| Inventories | 308 |
| Prepaid expenses and other current assets | -775 |
| Other noncurrent assets | 50 |
| Accounts payable and accrued expenses | -399 |
| Amounts due to related parties | -30 |
| Other current liabilities | -57 |
| Operating lease payments | -122 |
| Net cash used in operating activities | -4,739 |
| Proceeds from sale of property and equipment | 0 |
| Proceeds from sale of investments | 0 |
| Proceeds from sale of intangible assets | 750 |
| Cash paid related to sale of goodwheat | 0 |
| Purchases of property and equipment | 0 |
| Net cash provided by investing activities | 750 |
| Proceeds from espp purchases | 6 |
| Net cash provided by financing activities | 6 |
| Net decrease in cash and cash equivalents | -3,983 |
| Cash and cash equivalents - beginning of period | 4,242 |
| Cash and cash equivalents - end of period | 259 |
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)